[
    [
        {
            "time": "2023-03-15",
            "original_text": "Nordisk's (NVO) Oral Ozempic Positive in Diabetes Study",
            "features": {
                "keywords": [
                    "Nordisk",
                    "Oral Ozempic",
                    "Diabetes Study",
                    "Positive"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Nordisk's (NVO) Oral Ozempic Positive in Diabetes Study",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-03-16",
            "original_text": "Novo Nordisk Stock Rises 4% Over 2 Sessions",
            "features": {
                "keywords": [
                    "Novo Nordisk",
                    "Stock Rises",
                    "4%",
                    "Sessions"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Novo Nordisk Stock Rises 4% Over 2 Sessions",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-03-17",
            "original_text": "Novo Nordisk's (NVO) Oral Ozempic Positive in Diabetes Study",
            "features": {
                "keywords": [
                    "Novo Nordisk",
                    "Oral Ozempic",
                    "Diabetes Study",
                    "Positive"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Novo Nordisk's (NVO) Oral Ozempic Positive in Diabetes Study",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-03-18",
            "original_text": "European ADRs Move Lower in Thursday Trading",
            "features": {
                "keywords": [
                    "European ADRs",
                    "Move Lower",
                    "Thursday Trading"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "finance",
                    "international markets"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "European ADRs Move Lower in Thursday Trading",
                "Correlation": 3,
                "Sentiment": 4,
                "Importance": 5,
                "Impact": 3,
                "Duration": 4,
                "Entity_Density": 2,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 5,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-03-19",
            "original_text": "Novo Nordisk Stock Pops Nearly 3% on Positive Diabetes-Drug Results",
            "features": {
                "keywords": [
                    "Novo Nordisk",
                    "Stock Pops",
                    "3%",
                    "Diabetes-Drug Results",
                    "Positive"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Novo Nordisk Stock Pops Nearly 3% on Positive Diabetes-Drug Results",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-03-20",
            "original_text": "Novo Nordisk in Deal with Kallyope for Obesity, Diabetes Drugs",
            "features": {
                "keywords": [
                    "Novo Nordisk",
                    "Kallyope",
                    "Obesity",
                    "Diabetes Drugs",
                    "Deal"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Novo Nordisk in Deal with Kallyope for Obesity, Diabetes Drugs",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        }
    ]
]